CD8A and neoplasm: Genetic and pharmacological inhibition of PERK in CD8+ T cells abrogates mitochondrial ROS generation in programmed cell death protein-1+ CD8+ tumor-infiltrating lymphocytes (TILs), which bolsters CD8+ tumor-infiltrating lymphocyte viability and enhances antitumor immunity (70).